As radiologists become increasingly familiar faces on news sites and in police blotters, one Indiana University professor is suggesting the physicians might be prone to law-breaking due to their steep salaries and a professional culture centered around compliance.

President Donald Trump will deliver a speech on April 26 focused on ways to lower prescription drug prices, but the pharmaceutical industry doesn’t expect it to include the more dramatic reforms Trump espoused on the campaign trail.

The American Board of Radiology (ABR) made significant changes to its certification program for diagnostic radiologists in recent years, removing the oral component of the exam and relying on a standardized format with multiple-choice questions. This shift toward psychometric testing has made the certification program less reliable, according to a new analysis published by the Journal of the American College of Radiology, and the ABR should consider working with various stakeholders and education experts to change it.

Amazon has reportedly shelved plans to sell and distribute pharmaceuticals to hospitals and health systems through its Amazon Business unit, a move which analysts said illustrates the difficulty outside companies face in disrupting the existing healthcare supply chain.

On Friday, April 13, the FDA approved the latest version of the SOMATOM Force, a dual source CT system from Siemens Healthineers.

Prices across the healthcare sector rose 2.2 percent year-over-year in March 2018, the highest annual growth rate recorded by Altarum since January 2012, with the report warning rapid price growth is likely to continue.

The Rush hospital system based in Chicago has ended plans to acquire Little Company of Mary of Evergreen Park, Illinois, which would’ve merged 12 facilities with Rush University Medical Center and its 2,500-student health sciences college.

The report from the Health Care Cost Institute (HCCI) examined claims for people with multiple sclerosis (MS) from 2009 to 2015 covered by individual market, employer-sponsored or Medicare Advantage plans. It found total spending per MS patient rose from around $23,900 to $39,628 by 2015. During the same time period, the share of spending spent towards injectable and oral disease modifying therapies (DMTs) rose from 39 percent to 53 percent.